Related Experiment Video

Updated: Jun 10, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis

Gang Wang1, Sang Woong Youn2, Chia-Ling Chang3

  • 1Department of Dermatology, Xijing Hospital, Airforce Medical University, Xi'an, China.

Dermatology and Therapy
|June 9, 2026
PubMed

Biologic agents, including the interleukin-23 (IL-23) inhibitors (IL-23is) guselkumab, risankizumab, and tildrakizumab, are effective therapies for the treatment of psoriasis (PsO) and psoriatic arthritis (PsA). However, the risk of latent TB infection (LTBI) reactivation or new tuberculosis (TB) infection is of question, given documented evidence of occurrence of cases in patients with PsO and PsA treated with biologics with other mechanisms of action, and the relatively high prevalence of TB in some Asian Pacific (APAC) countries. We conducted a systematic literature review to summarize published evidence related to reactivation of LTBI or new TB infections among IL-23i-treated patients with PsO or PsA, with a focus on the APAC region. We searched the EMBASE, MEDLINE, MEDLINE In-Process, CNKI, Wanfang, ICHUSHI, KOREAMED, and AIRITI databases and gray literature sources for reports on randomized controlled trials and real-world observational studies reporting reactivation of LTBI or new TB infections among IL-23i-treated patients with PsO or PsA. A total of 58 publications from 41 studies met prespecified inclusion criteria, including 9 publications from 8 studies in APAC countries. No LTBI reactivation events or new TB cases were observed in 33 of 34 studies that enrolled IL-23i-treated patients with PsO, including patients with LTBI who did not complete chemoprophylaxis. In one observational study, LTBI reactivation was reported in a single risankizumab-treated patient. Similarly, no cases of LTBI reactivation or new TB cases were observed in 8 studies enrolling IL-23i-treated patients with PsA. The results summarized here suggest that the risks of new TB infections or LTBI reactivation are minimal among IL-23i-treated patients with PsO or PsA. Routine testing for LTBI in patients initiating IL-23i treatment should not be required, particularly in regions with low TB prevalence.

Keywords:
BiologicsPsoriasisPsoriatic arthritisSafetyTuberculosis

Related Concept Videos

Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...